Star Probiotics-WecLac Lactobacillus Rhamnosus LRa05

No.1 strain advantage

Health efficacy verification

1、Gut health

LRa05 exhibits strong adhesion, can counteract Shigella, adjust intestinal permeability, increase ileum tightness, and has high performance in resisting acute diarrhea. LRa05 can also alleviate oxidative stress reactions by regulating levels of pro-inflammatory and anti-inflammatory factors. Additionally, it can increase the abundance of lactobacilli in the gut, thus promoting a healthy gut microbiota.

Related Clinical/Literature/Patents

1. Intervention study of Lactobacillus rhamnosus LRa05 to improve acute watery diarrhea in children.   

2. A Lactobacillus rhamnosus LRa05 antagonizing Shigella, screening method and its application.

3. The use of Lactobacillus rhamnosus LRa05 in non-therapeutic destinations for the inhibition of pathogenic bacteria and/or the preparation of constipation-relieving products or products for the mediation of intestinal flora.

4. The use of a Lactobacillus rhamnosus LRa05 in the preparation of preparations for the improvement of irritable bowel syndrome.

5. A Lactobacillus rhamnosus strain LRa05 and its uses and products.

6. Tian Y. Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model.

7. Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study.

2、Blood Sugar Health

LRa05 regulates insulin resistance and protects the normal functioning of pancreatic islets in type 2 diabetes. Experimental evidence demonstrates the remarkable ability of LRa05 to regulate serum ALT, AST levels, serum inflammatory factors, and fasting blood glucose levels.

Using a high-fat diet and streptozotocin (STZ) injection, a type 2 diabetes mouse model was established. The results showed that the fasting blood glucose and postprandial blood glucose levels in the LRa05 prevention group and treatment group were significantly lower than those in the model group, indicating that LRa05 has a good preventive effect on type 2 diabetes. Therefore, LRa05 probiotics have broad market prospects in the preparation of drugs, foods, or health products for the prevention or treatment of type 2 diabetes.

Changes in fasting and postprandial blood glucose levels in mice

The normal group (N), model group (M), drug treatment group (P), L. rhamnosus LRa05 prevention group (LR), L. rhamnosus LRa05 treatment group (LR). A, fasting blood glucose; B, postprandial blood glucose.

Related clinical/literature/patents

1. clinical efficacy and evaluation of Lactobacillus rhamnosus LRa05 in the treatment of type 2 diabetes mellitus

2. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice.

3. Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism.

3、Weight Management

Through its regulatory effects on perirenal fat or abdominal wall fat, the application of LRa05 has creatively developed a novel strategy for weight loss and lipid reduction, demonstrating potential market value.

Related clinical/literature/patents

1. A compound probiotic for inhibiting fat accumulation and its application

4、Skin Health

LRa05 exhibits strong antimicrobial capabilities, excellent anti-inflammatory and immune-regulatory functions. It has a regulatory effect on mouse splenic lymphocyte transformation value, cellular inflammatory factors, and levels of intestinal short-chain fatty acids. LRa05 can promote immune cell activity, reduce inflammatory responses, and significantly improve symptoms in patients with eczema.

Related clinical/literature/patents

1. Efficacy and safety of Lactobacillus rhamnosus strain LRa05 in reducing atopic dermatitis score index in children

2. Use of Lactobacillus rhamnosus strain LRa05 in the preparation of immune-enhancing products and/or eczema-relieving products

No.2 strain advantage

Stronger flora regulation and tolerance

1. Inhibit harmful bacteria

The decreased abundance of Salmonella infection and NOD-like receptor signaling pathways, increased abundance of nitrogen metabolism pathways, and decreased abundance of Salmonella infection pathways in the LRa05 group compared to the CTL group implies that LRa05 has inhibitory potential against harmful bacteria.

Lactobacillus rhamnosus LRa05 has inhibitory potential against harmful bacteria

2. Increasing the abundance of Lactobacillus

Both placebo and LRa05 interventions resulted in significant changes in the composition of the gut microbiota at T1 relative to T0, and these changes primarily involved significant reductions in the relative abundance of Firmicutes and Actinobacteria as well as a significant increase in the relative abundance of the Anaplasma phyla.

Abundance map of Lactobacillus rhamnosus LRa05 post-intervention flora

3. High Tolerance

Lactobacillus rhamnosus LRa05 was well tolerated with 88% survival after 2h of action at simulated gastric acid pH3.0 and 81% survival after 2h of action at simulated bile salt concentration of 0.3%.

Acid and bile salt resistance trial of Lactobacillus rhamnosus LRa05

No.3 strain advantage

Wider range of applications

Lactobacillus rhamnosus LRa05 is a highly tolerant probiotic strain with outstanding resistance to gastric acid and bile, which colonizes the intestinal epithelial cells and can become a biological barrier to the intestinal mucosa, thus enhancing the barrier ability of the intestinal mucosa of the host.LRa05 has a strong ability to remove pathogenic bacteria, hindering the colonization of pathogenic bacteria in the body, and increasing the abundance of Lactobacillus, which can be widely used in the regular food, health food and pharmaceutical fields.

No.4 strain advantage

Enterprise qualification certification

Focus on value recognition

We offer you Lactobacillus rhamnosus LRa05 with activity ≥800 billion CFU/g.

Service Hotline: 400-8518-553

Some literature sources:

1. a Lactobacillus rhamnosus strain LRa05 antagonizing Shigella, screening method and its application (ZL202010793756.1)

2. the use of Lactobacillus rhamnosus strain LRa05 in the preparation of products for the inhibition of Helicobacter pylori and/or Streptococcus mutans (CN202210382754.2 pending)

3. Use of Lactobacillus rhamnosus strain LRa05 in the preparation of immunity-enhancing products and/or eczema-relieving products (CN202210382762.7 application)

4. Use of a strain of Lactobacillus rhamnosus LRa05 in the preparation of preparations for ameliorating irritable bowel syndrome (CN202210408975.2 application)

5. A Lactobacillus rhamnosus strain LRa05 and its uses and products (CN202210382570.6 in application)

6. Use of Lactobacillus rhamnosus LRa05 in the inhibition of pathogenic bacteria for non-therapeutic destinations and/or in the preparation of constipation-relieving products or products for the mediation of intestinal flora (CN202210382569.3 in application)

7. Lactobacillus rhamnosus LRa05 against Candida vaginitis and its applications (CN202211151013.X in application)

8. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice.

9. Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism. Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism.